Here are five points:
1. The underwriters purchased an additional 560,000 shares of common stock.
2. The offering now totals about $32.2 million, before removing underwriting discounts and commissions.
3. InVivo offered 3,733,333 units at a price of $7.50 per unit, in connection with the offering’s closing on March 18.
4. At the initial closing, the underwriters exercised their over-allotment option to buy an additional 280,000 shares of common stock.
5. The company will use the net proceeds to finance clinical trials and corporate expenses.
More articles on devices:
Cervical total disc replacement device market to hit $1.8B — 4 notes
Lakeway Regional Medical Center now a CarboClear Pedicle Screw System study site: 5 observations
Magnesium Development Company raises $1M for new orthopedic device alloy: 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
